


PrEP Medications



There are three FDA-approved oral medications for pre-exposure prophylaxis (PrEP): F/TDF Generic, Truvada®, and Descovy®. All are safe and highly effective in clinical trials. There were no differences in adverse clinical outcomes such as broken bones or heart disease between people taking either regimen. Choice may be limited by insurance coverage.

	Generic or Truvada® Tenofovir disoproxil fumarate 300 mg + Emtricitabine 200 mg (F/TDF) <i>generic version available</i>	Descovy® Tenofovir alafenamide 25 mg + Emtricitabine 200 mg (F/TAF)
Indications	F/TDF is approved for use for all adults and adolescents ≥35 kg with indications for PrEP	F/TAF is approved for use for adults and adolescents ≥35 kg at risk for sexually acquired HIV, excluding individuals at risk only from receptive vaginal sex or only from injection drug use
Dosing	1 pill once daily unless using a PrEP 2-1-1 schedule	1 pill once daily
"On Demand" PrEP: 2-1-1 Dosing <i>This strategy has not yet been reviewed by the FDA, but is recommended by the CDC in their 2021 PrEP Guidelines</i>	2-1-1 for people with anal exposures only: 2 pills 2-24 hours before anal sex (24 hours before for optimal protection) <ul style="list-style-type: none"> • then 1 pill 24 hours after first dose • then 1 pill 24 hours after second dose For a detailed 2-1-1 prescribing guide, refer to the CDC's 2021 PrEP Guidelines	The PrEP 2-1-1 dosing schedule is not recommended for use with F/TAF (Descovy®) outside of a clinical trial
Side Effects	Generally safe and well tolerated <ul style="list-style-type: none"> • Headache and abdominal discomfort which often resolves in a few weeks • Weight loss • Small decrease in eGFR, which improves upon discontinuation of F/TDF 	Generally safe and well tolerated <ul style="list-style-type: none"> • Abdominal discomfort, nausea, and headache, which often resolves in a few weeks • Small increase in LDL cholesterol • Slight increase in body weight
Other Notes	Estimated GFR or CrCl by serum labs should be ≥60 ml/min to safely use F/TDF	Estimated GFR or CrCl by serum labs should be ≥30 ml/min to safely use F/TAF


Questions?

Call The National Clinicians Consultation Center
 PrEPline at 1-855-448-7737

PrEP Medications



The US Food and Drug Administration (FDA) has approved one injectable pre-exposure prophylaxis (PrEP) medication: cabotegravir (CAB) 600 mg (brand name Apretude®). CAB is a single antiretroviral drug given as an intramuscular injection every 2 months to prevent HIV. This option may be limited by insurance coverage.

Injectable PrEP 	Apretude® Cabotegravir 600 mg
Indications	<p>In 2021, the US Preventative Services Task Force issued a graded recommendation to prescribe Cabotegravir (CAB) for PrEP to adult patients who are at risk of getting HIV through sex (grade IA).</p>
How is Injectable PrEP Used?	<p>CAB is FDA approved as an intramuscular injection in the buttocks initiated as a first injection followed by a second injection 1 month after the first and then continued with an injection every 2 months thereafter. A 4-week lead-in period of 30 mg daily oral CAB prior to the first injection is optional for patients who are worried about side effects.</p>
Baseline Assessments	<p>Perform the following baseline assessments for all injectable PrEP candidates:</p> <ul style="list-style-type: none"> • HIV Testing: Confirm that the patient does not have HIV before prescribing PrEP. CDC guidelines using HIV-1 RNA assay to rule out acute infection. • STD Testing: Screen injectable PrEP candidates who are sexually active for chlamydia, gonorrhea, and syphilis.
Clinical Follow-up and Monitoring	<p>Once CAB injections are initiated, patients should return for follow-up visits 1 month after the initial injection and then every 2 months.</p> <p>At each bimonthly visit (beginning with the third injection - month 3)</p> <ul style="list-style-type: none"> • Repeat HIV-1 RNA test and assess for signs and symptoms of acute infection • Administer CAB injection. • Provide access to clean needles/syringes and substance treatment services for PWID • Respond to new questions and provide new information about CAB PrEP • Discuss the benefits of persistent CAB PrEP use and adherence to scheduled injections <p>At least every 4 months (every other injection visit)</p> <ul style="list-style-type: none"> • Conduct STD screening for MSM and transgender women who have sex with men - oral, rectal, urethral, blood <p>At least every 6 months</p> <ul style="list-style-type: none"> • Conduct STD screening for all heterosexually active women and men

Questions?

Call The National Clinicians Consultation Center
PrEPline at 1-855-448-7737